Search clinical trials for: Azilsartan medoxomil and olmesartan

Total 220 results

Lee's Pharmaceutical Limited

Completed

Azilsartan in Chinese Patients With Mild and Moderate Hypertension

Hypertension

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Essential Hypertension

China
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Hypertension

United States, Mexico, Argentina
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Essential Hypertension

United States, Canada
Takeda

Completed

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

Essential Hypertension

United States, Chile, Mexico
Takeda

Completed

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Safety

Ukraine, Germany, Poland, Bulgaria, Netherlands, Lithuania, Slovakia, Latvia
Takeda

Completed

Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

Essential Hypertension

Netherlands, Austria, Germany, Poland, United Kingdom
Shenzhen People's Hospital

Recruiting

s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension

Essential Hypertension

China
Takeda

Completed

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

Hypertension

United States, Argentina, Peru, Mexico
University of Chicago
Takeda

Completed

Effect of Azilsartan on Aldosterone in Postmenopausal Females

Hypertension

United States
Daiichi Sankyo, Inc.

Completed

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Hypertension

United States, Colombia, Argentina, Peru, Brazil, Kenya, Chile, South Africa, India, Zambia, Uganda
Takeda

Completed

Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension

Hypertension
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Terminated

Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 (OLMEBNP)

Chronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level

Germany, France, Netherlands
Tohoku University

Completed

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT)

Chronic Heart Failure

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy

Diabetic Nephropathy | Chronic Glomerulonephritis

Japan
Celltrion Pharm, Inc.

Completed

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

Essential Hypertension

Korea, Republic of
Central South University

Completed

Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers

Drug Interaction of Olmesartan in Healthy Chinese Volunteers

China
Arbor Pharmaceuticals, Inc.

Completed

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

Hypertension

United States, Brazil, Turkey, Poland, Mexico, Colombia, Italy, Argentina, Bulgaria, Hungary, South Africa, Ukraine
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (ArtStiff)

Hypertension | Metabolic Syndrome

Italy, Belgium, Germany
Virginia Polytechnic Institute and State University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Angiotensin II Blockade and Inflammation in Obesity (ARB)

Hypertension | Overweight | Prehypertension | Obese
Takeda

Completed

International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

Hypertension

Russian Federation, Kazakhstan
Takeda

Completed

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Type 2 Diabetes Mellitus | Essential Hypertension

Taiwan, Thailand, China
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension

Essential Hypertension

Japan
Daiichi Sankyo, Inc.

Completed

Olmesartan Pediatric Pharmacokinetic (PK) Study

Hypertension

United States
Daiichi Sankyo, Inc.

Completed

A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis

Atherosclerosis
Daiichi Sankyo Co., Ltd.

Completed

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria

Japan, China
Pfizer

Completed

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Hypertension
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Daiichi Sankyo, Inc.

Completed

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

Hypertension

United States
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

France, Poland, Ukraine, Germany, Spain, Bulgaria, Czechia
Takeda

Terminated

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

Hypertension

United States, United Kingdom
Research Institute for Complex Problems of Cardiovascular...

Completed

Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus. (AcADEME)

Diabetes Mellitus | Arterial Hypertension | Stable Chronic Angina

Russian Federation
Lee's Pharmaceutical Limited
Zhaoke (Guangzhou) Pharmaceutical Limited

Completed

Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers

Bioequivalence of Two Azilsartan Formulations

Hong Kong
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil and Diabetic Nephropathy

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria | Renal Disease

Poland, Spain, Estonia, Czech Republic, Germany, Slovakia, Netherlands
Seoul National University Bundang Hospital

Completed

Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension (Ang(1-7))

Hypertension | Diabetes Mellitus, Type 2 | Angiotensin/Renin/Aldosterone Hypertension

Korea, Republic of
Takeda

Completed

Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension

Hypertension

Korea, Republic of
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Hypertension

United States
Daiichi Sankyo, Inc.
Shanghai Sankyo Pharmaceuticals Co., Ltd.

Completed

Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

Essential Hypertension

China
Daiichi Sankyo Co., Ltd.

Completed

Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension

Hypertension

Japan
Mylan Pharmaceuticals Inc

Completed

Fasting Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

Healthy

United States
Sankyo Pharma Gmbh

Completed

Olmesartan Medoxomil in Diabetes Mellitus

Cardiovascular Disease | Diabetes Mellitus, Type 2 | Kidney Disease

Germany
Sankyo Pharma Gmbh

Completed

Olmesartan in Essential Hypertension

Essential Hypertension

Austria, Germany, Italy, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Lee's Pharmaceutical Limited

Completed

Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers

Hypertension
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
Daiichi Sankyo, Inc.

Completed

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension

Hypertension

United States
EMS

Not yet recruiting

Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control

Arterial Hypertension
Daiichi Sankyo, Inc.

Completed

The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects

Healthy
Takeda

Completed

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

Hypertension

United States, Mexico, Chile, Peru
China Medical University Hospital

Unknown

Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue

Stroke | Fatigue

Taiwan
Boryung Pharmaceutical Co., Ltd

Completed

Fimasartan Achieving SBP Target (FAST) Study (FAST)

Essential,Hypertension

Korea, Republic of

3

Subscribe